Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 48
Summary
- Conditions
- Peanut Allergy
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 6 years and 17 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03793608
- Collaborators
- Sanofi
- Investigators
- Study Director: Clinical Trial Management Regeneron Pharmaceuticals